Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kimikazu Fujita is active.

Publication


Featured researches published by Kimikazu Fujita.


Journal of Neuroscience Research | 1996

Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis

Kimikazu Fujita; Masamitsu Yamauchi; K. Shibayama; Masato Ando; M. Honda; Yutaka Nagata

The cause of selective degeneration of motor neurons in the ventral horn of the spinal cord associated with amyotrophic lateral sclerosis (ALS) has still not been elucidated. Recently, so‐called oxidative stress has been suggested to be a significant factor in the pathogenesis of this disease. We measured the antioxidant actions of superoxide dismutase (SOD), glutathione peroxidase (GSH‐Px), and cytochrome c oxidase (CO) of the human spinal cord in patients with ALS in comparison with those in control patients. Total SOD activity in spinal cord transections from patients with sporadic ALS was not significantly different from the controls in ventral, lateral, or dorsal regions, although enzymic activity was relatively higher in the ventral compared with the dorsal region. GSH‐Px activity in the spinal cord of ALS patients was not very different from that in the control tissue. In contrast, CO activity was significantly reduced in all three regions of the spinal cord in patients with ALS, although the reduction was more marked in the ventral region. These results suggest that reactive oxygen species may attack the mitochondrial respiratory chain, leading eventually to the degeneration of vulnerable motor neurons in the spinal cord, even though no obvious changes in the activity of antioxidant enzymes are detectable.


Journal of Neurochemistry | 1978

SERUM DOPAMINE‐β‐HYDROXYLASE IN SCHIZOPHRENIC PATIENTS

Kimikazu Fujita; T. Ito; K. Maruta; R. Teradaira; H. Beppu; Y. Nakacami; Y. Kato; Toshiharu Nagatsu; Takeshi Kato

Abstract— Dopamine‐β‐hydroxylase (DBH) activity in serum was decreased significantly in schizophrenic patients (16.17 ± 12.60 μmol/min/1 of serum, mean ± S.D., n = 149) when compared with that of normal controls (42.53 ± 30.94 μmol/min/1 of serum, mean ± S.D., n= 153) and neurotic patients. Long duration of disease did not cause any significant changes in serum DBH activity except a tendency for increase in patients of lodger than 18 years duration. We also examined the possibility that the serum DBH deficiency in the schizophrenic group was an artifact of treatment with antipsychotic drugs, especially phenothiazines. No significant difference was observed between the patients treated with the drugs and the patients not receiving the drugs.


Archives of Dermatological Research | 1987

Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect

Miura S; T. Ueda; Kowichi Jimbow; Shosuke Ito; Kimikazu Fujita

SummaryPhenolic and catecholic compounds were synthesized, by combination with cysteine or cysteamine through thioether bond, and their antimelanoma and melanocytotoxic effects were evaluated. Among nine compounds tested, 4-S-cysteaminylphenol (CAP) resulted in an increase in the life span (% ILS) of melanoma-bearing mice and in the growth inhibition (% GI) of melanoma tissue. 4-S-Cysteinylphenol (CP) and its methyl ester form also showed some increase in % GI. The 2-S-isomers of CP and CAP and diphenolic derivatives of CP did not show any significant antimelanoma effect. In addition, the s.c. injection of 4-S-CAP and 4-S-CP, in particular 4-S-CAP, caused the depigmentation of black hair which was manifested by loss of functioning melanocytes, as seen under light microscopy. The 4-S-CAP appears to provide a basis for development of a new class of antimelanoma and melanocytotoxic agents that are more stable than catecholic compounds, which have been most widely utilized as a source of rational chemotherapy for malignant melanoma.


Neurochemical Research | 1995

Alteration of Transglutaminase Activity in Rat and Human Spinal Cord after Neuronal Degeneration

Kimikazu Fujita; Masato Ando; Masamitsu Yamauchi; Yutaka Nagata; Masao Honda

We measured the activity of transglutaminase (TG), a Ca2+-dependent enzyme and a biochemical marker of cell degeneration, in the adult rat spinal cord after unilateral occlusion of a branch of the dorsal spinal artery, and compared it to the enzyme activity in the tissue on the contralateral side without ischemic damage. The affected half of the spinal cord showed a significant rise in intrinsic (endogenous) TG activity one day after ischemic insult while no apparent morphological changes were observed in the tissue. However, the enzymic activity on the affected side gradually decreased to reach the level in the non-affected tissue, accompanying severe degeneration of neuronal cells at 7 days after the surgery, then it declined to nearly half the level in the intact tissue 30 days after the operation. We also determined the TG activity in transverse sections of the human spinal cord obtained at autopsy from 5 amyotrophic lateral sclerosis (ALS) and 9 non-ALS patients. TG activity in thoracic and lumbar cords was markedly low in ALS patients not only in ventral and lateral regions but also in the dorsal portion. These findings imply that the reduced TG activity in the ALS spinal cord is one of the characteristic features of the disease reflecting exhaustion of the enzyme in the tissue resulting from degeneration of the spinal neurons through cross-linkage of soluble intraneuronal cytoplasmic proteins.


Brain Research | 1998

Increase of glial fibrillary acidic protein fragments in the spinal cord of motor neuron degeneration mutant mouse

Kimikazu Fujita; Masamitsu Yamauchi; Taei Matsui; Koiti Titani; Hisahide Takahashi; Toshiaki Kato; Genzoh Isomura; Masato Ando; Yutaka Nagata

We analyzed protein fractions extracted from the spinal cord of the motor neuron degeneration (Mnd) mouse, a mutant that exhibits progressive degeneration of lower spinal motor neurons, by one- and two-dimensional polyacrylamide gel electrophoresis (PAGE) after solubilization of the tissue with medium containing sodium dodecyl sulfate (SDS)-urea during growth of the animal, in comparison with those of age-matched controls (C57BL/6). Several protein spots were detected around a region of pI 5.6-6.0 and molecular mass of 35-50 kDa in Mnd spinal cord tissue on the two-dimensional PAGE separation profile with Coomassie brilliant blue staining, while only a few spots around the same region were found in the control spinal cord. These spots were all immunoreactive with an antibody against glial fibrillary acidic protein (GFAP), a cytoskeleton filamentous protein specific to astroglial cells. The protein spot with molecular mass of 50 kDa showed immunoreactivity with anti-GFAP antibody, had a blocked amino-terminus, and is assumed to be intact GFAP. Several protein spots with slightly smaller molecular masses of 35 to 48 kDa lacked the head domain of the GFAP molecule as a result of cleavage at the 29th and 56th residues from the amino terminus. In Mnd spinal cord tissue, the densities of the immunoreactive GFAP bands with smaller molecular masses increased with development, and became dominant at the time of the appearance of behavioral paralytic gait around 6 to 7 months of age. These results suggest that the increased GFAPs devoid of head domains are related to the degenerative loss of motor neurons in the Mnd spinal cord. Histopathological and GFAP immunohistochemical examination of Mnd spinal cord preparation demonstrated progressive degenerative loss of motor neurons, and considerable increases in number of GFAP-stained astrocytes in the ventral horn at 7 to 9 months of age. These processes of degenerative loss of motor neurons and proliferation of reactive astrocytes with increased levels of fragmented GFAP in the Mnd spinal cord during development seem to be characteristic and preceded the deterioration of motor activities in this animal model of amyotrophic lateral sclerosis.


Neurochemical Research | 2006

Protective Effect Against 17β-Estradiol on Neuronal Apoptosis in Hippocampus Tissue Following Transient Ischemia/Recirculation in Mongolian Gerbils via Down-Regulation of Tissue Transglutaminase Activity

Kimikazu Fujita; Toshiaki Kato; K. Shibayama; Hideki Imada; M. Yamauchi; Nobuko Yoshimoto; Ei-ichi Miyachi; Yutaka Nagata

We analyzed the protective effect of 17β-estradiol (17β-ED) injection against delayed neuronal death in the hippocampus tissue of the brain in Mongolian gerbils after transient ischemia/recirculation treatment, especially in relation with bcl-2 gene expression and enzymatic activity changes of caspase-3 and tissue transglutaminase (tTGase). Daily intraperitoneal injection of 17β-ED to the animal after the ischemia stimulated the expression of an apoptosis suppressor gene, bcl-2, in the hippocampal tissue for a week. The gradually increasing apoptotic enzyme activity of caspase-3 and increased number of TUNEL positive fragmented neuronal nuclei caused by ischemic attack in the gerbil brain were clearly suppressed by 17β-ED administration. The reduced activity and enzyme protein of tTGase, a neurodegenerative marker of apoptosis in the hippocampus after ischemia, were also restored to nearly normal levels by 17β-ED injection. These results suggest that daily 17β-ED administration to the gerbil after transient ischemic insult with progressing neuronal deteriorative changes in hippocampus tissue can effectively prevent apoptotic changes through a molecular cascade involving gene expression regulation.


Journal of Neurochemistry | 1977

Dopamine‐ß‐hydroxylase activity in human cerebrospinal fluid and serum

Kimikazu Fujita; K. Maruta; R. Teradaira; H. Beppu; K. Shinpo; Y. Maeno; T. Ito; Toshiharu Nagatsu; Takeshi Kato

DOPAMINE-a-hydroxytase (DBH) in serum is secreted from peripheral sympathetic nerve terminals together with noradrenaline and may have some correlation with the activity of peripheral noradrenergic neurones (AXELROD, 1973). The enzyme has been found in rabbit (DE POTTER, 1976) and human (GOLDSTEIN & CUBEDDU, 1976; OKADA er al., 1976) cerebrospinal fluid, and may be derived from central noradrenergic neurones. We have devised a highly sensitive new fluorometric assay for DBH activity by high-performance liquid chromatography (FUIITA et a]., in preparation), and applied this method to the assay of DBH activity in human cerebrospinal fluid. The DBH activity in human cerebrospinal fluid was compared with that in serum. Cerebrospinal fluid was obtained from patients at Fujita-Gakuen University School of Medicine Hospital by lumbar puncture. The patients were undergoing surgery under lumbar anesthesia. No patient suffering from central or peripheral neurological disease was included, and the general physical and nutritional states of the patients were within the normal range. The first 5ml was removed for chemical and cytological examination, and the next 5ml was used for the assay of bBH activity. The samples of cerebrospinal fluid were all clear, and no red cells were detected. Blood samples were obtained by venepuncture and serum was separated.


Neurochemical Research | 1998

Increases in Fragmented Glial Fibrillary Acidic Protein Levels in the Spinal Cords of Patients with Amyotrophic Lateral Sclerosis

Kimikazu Fujita; Toshiaki Kato; Masamitsu Yamauchi; Masato Ando; Masao Honda; Yutaka Nagata

Using one-dimensional polyacrylamide gel electrophoresis, we analyzed protein fractions extracted from the spinal cords of patients with amyotrophic lateral sclerosis (ALS). Several protein bands with molecular weights of 35–55 kDa were stained with Coomassie brilliant blue much more intensely in the ALS than in the non-ALS spinal cord. Glial fibrillary acidic protein (GFAP) immunoreactivity showed a significant decrease of 50 and 45 kDa band and increase in fragmented 36 and 37 kDa bands, which represented GFAP fragments devoid of 59 and 40 residues from the N-terminal, respectively, as determined by protein sequence analysis. Immunohistochemical examination of ALS spinal cord transections demonstrated increased GFAP-stained astrocytes in the shrunken ventral horn with massive degeneration of motoneurons. These results will provide new insight into the possible role of astrocytes in the pathophysiology and/or pathogenesis of ALS.


Neurochemical Research | 1998

Alteration of Enzymatic Activities Implicating Neuronal Degeneration in the Spinal Cord of the Motor Neuron Degeneration Mouse During Postnatal Development

Kimikazu Fujita; K. Shibayama; Masamitsu Yamauchi; Toshiaki Kato; Masato Ando; Hisahide Takahashi; K. Iritani; N. Yoshimoto; Yutaka Nagata

Oxidative stress is suggested as a significant causative factor forpathogenesis of neuronal degeneration on spinal cord of human ALS. Wemeasured some enzymic activities implicating neuronal degenerationprocess, such as cytochrome c oxidase (CO), superoxidedismutase (SOD), and transglutaminase (TG) in spinalcord of an animal model of ALS, motor neuron degeneration(Mnd) mouse, a mutant that exhibits progressivedegeneration of lower spinal neurons during developmental growth, andcompared them with age-matched control C57BL/6 mice. CO activity inMnd spinal cord decreased during early postnatal period, whileSOD activity reduced in later stage. In Mnd tissue, TG activityin lumbar cord was increasing during early stage, but tended to declinein later period gradually. These biochemical alterations became evidentprior to the appearance of clinical motor dysfunction which wereobserved in later stages of development in Mnd spinal cord.


Molecular and Chemical Neuropathology | 1998

Neurochemical changes in the spinal cord in degenerative motor neuron diseases

Yutaka Nagata; Kimikazu Fujita; Masamitsu Yamauchi; Toshiaki Kato; Masato Ando; Masao Honda

Human amyotrophic lateral sclerosis (ALS), a typical motor neuron disease, is characterized pathologically by selective degenerative loss of motoneurons in the CNS. We have demonstrated significant reductions of neurotransmitter-related factors, such as acetylcholine-(ACh)-synthesizing enzyme activity and glutamate and aspartate contents in the ALS, compared to the non-ALS spinal cord obtained at autopsy. We have also shown considerable reductions in activities of cytochrome-c oxidase (CO), an enzyme contributing to aerobic energy production, and transglutaminase (TG), a Ca(2+)-dependent marker enzyme for tissue degeneration, in the ALS spinal cord. We found marked increases in fragmented glial fibrillary acidic protein (GFAP), a filamentous protein specifically associated with reactive astrocytes, in the ALS spinal cord relative to non-ALS tissue. These biochemical results corresponded well to pathomor-phological neuronal degenerative loss and reactive proliferation of astroglial components in the ALS spinal cord tissue. However, these results only indicate the final pathological and biochemical outcomes of ALS, and it is difficult to follow up cause and process in the ALS spinal cord during progression of the disease. Therefore, we used an animal model closely resembling human ALS, motor neuron degeneration (Mnd) mutant mice, a subline of C57BL/6 that shows late-onset progressive degeneration of lower motor neurons with paralytic gait beginning around 6.5 mo of age, to follow the biochemical and pathological alterations during postnatal development. We detected significant decreases in CO activity during early development and in activity of superoxide dismutase (SOD), an antioxidant enzyme, in later stages in Mnd mutant spinal cord tissue. TG activity in the Mnd spinal cord showed gradual increases during early development reaching a maximum at 5 mo, and then tending to decrease thereafter. Amounts of fragmented GFAPs increased continuously during postnatal development in Mnd spinal cord. These biochemical changes were observed prior to the appearance of clinical motor dysfunctions in the Mnd mutant mice. Such biochemical analyses using appropriate animal models will be useful for inferring the origin and progression of human ALS.

Collaboration


Dive into the Kimikazu Fujita's collaboration.

Top Co-Authors

Avatar

Yutaka Nagata

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshiaki Kato

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar

Masato Ando

Aichi Gakusen University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuhiro Maruta

Tokyo Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hideki Imada

Fujita Health University

View shared research outputs
Top Co-Authors

Avatar

Masao Honda

Yokohama City University

View shared research outputs
Researchain Logo
Decentralizing Knowledge